Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials

Main Article Content

Mark Lebwohl
April W Armstrong
Joseph F Merola
Alice B Gottlieb
Leah Davis
Braulio Gomez
Susanne Wiegratz
Nancy Cross
Bruce Strober


bimekizumab, psoriasis, biologic, efficacy




1. Wade R et al. Systematic Reviews 2020; 9:132;

2. Warren RB et al. N Engl J Med 2021;385:130–141, NCT03412747;

3. Reich K et al. Lancet 2021;397:487–498, NCT03370133;

4. Gordon KB et al. Lancet 2021;397:475–486, NCT03410992;

5. Reich K et al. N Engl J Med 2021;385:142–152, NCT03536884.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 8 9 10 11 12 13 14 15 16 17 > >>